A major Cochrane review of 17 clinical trials involving over 20,000 participants has concluded that drugs targeting amyloid beta in the brain provide no meaningful benefits for patients with mild cognitive impairment or early Alzheimer’s. These treatments also raise the risk of brain swelling and bleeding. Researchers urge a shift to alternative pathways for future treatments.
Anti-amyloid drugs, developed to clear protein deposits believed to drive Alzheimer’s disease, show little clinical value despite reducing amyloid levels, according to a new Cochrane systematic review. The analysis pooled data from 17 trials with 20,342 participants, all focused on people with mild cognitive impairment or early-stage dementia. Effects on memory and disease severity fell well below thresholds considered meaningful in practice, researchers found. The review appears in the Cochrane Database of Systematic Reviews, published in 2026 (4), with DOI: 10.1002/14651858.CD016297. Materials were provided by Cochrane, as reported by ScienceDaily. “Unfortunately, the evidence suggests that these drugs make no meaningful difference to patients,” said lead author Francesco Nonino, a neurologist and epidemiologist at the IRCCS Institute of Neurological Sciences of Bologna, Italy. He noted that while early trials showed statistical significance, this did not translate to real-world benefits. Safety concerns emerged prominently, with the drugs linked to higher rates of brain swelling and bleeding, often detectable only on scans without symptoms. Long-term impacts remain unclear due to inconsistent reporting across studies. “I see Alzheimer’s patients in my clinic every week and I wish I had an effective treatment to offer them,” said senior author Edo Richard, Professor of Neurology at Radboud University Medical Centre. He highlighted the unmet need and called for exploring other biological pathways beyond amyloid removal.
